Neoadjuvant Atezolizumab and Nab-Paclitaxel for Anthracycline-Resistant Early-Stage TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Breast Cancer Research and Treatment
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer
Breast Cancer Res Treat 2023 Jun 01;199(3)457-469, C Yam, EA Mittendorf, HR Garber, R Sun, S Damodaran, RK Murthy, D Ramirez, M Karuturi, RM Layman, N Ibrahim, GM Rauch, BE Adrada, RP Candelaria, JB White, E Ravenberg, A Clayborn, QQ Ding, WF Symmans, S Prabhakaran, AM Thompson, V Valero, D Tripathy, L Huo, SL Moulder, JK LittonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.